Marketing of Eli Lilly Drugs Faces New Probe
- Share via
Eli Lilly & Co., already under federal investigation for the way it promoted an osteoporosis drug, said it faced a new federal probe of its marketing practices.
The Indianapolis-based company said it believed the new probe also probably focuses on the osteoporosis drug Evista, as well as its top seller, antipsychotic drug Zyprexa, and antidepressant Prozac.
Lilly, one of several drug makers to come under federal scrutiny over marketing issues, said the U.S. attorney for the Eastern District of Pennsylvania has begun a civil inquiry.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
